By: Ana Elcarte

Columbus VP leads the new investment round of Integra Therapeutics with €1.5M
30/03/2022

The biotechnology firm completes the seed round funding with a total of €6 million led last December by AdBio Partners, Invivo... Read More
Artax Biopharma Announces First-in-Human Dosing for AX-158
16/12/2021

First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company's First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases The Phase 1... Read More
Aleta Biotherapeutics Announces ALETA-001
13/12/2021

Aleta Biotherapeutics Announces ALETA-001 Poster Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting Pre-clinical results demonstrate durable response... Read More
Vifor Pharma to acquire Sanifit
22/11/2021

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical... Read More
Highlight Therapeutics: Positive Phase 2b results in 2nd line melanoma
16/11/2021

Highlight Therapeutics presents a medical breakthrough at the SITC oncology congress, being the first time that a drug shows a positive... Read More
Aura Biosciences is trading on the Nasdaq Global Market
04/11/2021

Columbus Venture Partners Portfolio Company, Aura Biosciences, is trading on the Nasdaq Global Market Aura Biosciences (Cambridge, USA), whose founder is... Read More
Arcline Investment Management Acquires PTS
28/04/2021

VALENCIA, Spain, April 27, 2021 -- Arcline Investment Management ("Arcline"), a growth-oriented private equity firm with $4.3 billion of cumulative capital commitments, today announced the... Read More
Columbus close its third Investment Biotech Fund with 120€M
26/04/2021

 Read complete article here Read More
Vivet Therapeutics announces agreement with Mirum Pharmaceuticals
13/04/2021

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial... Read More
Aura Biosciences Announces Oversubscribed $80 Million Financing
22/03/2021

CAMBRIDGE, March 2021 -- Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for... Read More